CONCORD, Ohio--(BUSINESS WIRE)-- Dermal toxicity experts at Ricerca Biosciences, an integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, led a webinar discussing the topic, ‘Dermal Toxicity Study Design and Methodology.’ The interactive discussion covered the challenges facing effective study design and execution.
The webinar discussed the implications for animal welfare, as well as current study designs and techniques used for dermal studies. During the webinar, Ricerca shared its experience with the use of behavioral conditioning using enhanced food rewards as a means of significantly reducing animal handling and stress during dermal dosing as part of its ongoing animal welfare program.
Topics covered during the June 23, 2011, live webinar included:
- Dermal and photo toxicity and other routes of administration for improving systematic exposure
- Histopathology/skin structure and choice of species
- Regulations and what is required for these types of products
“Ricerca has invested heavily in its people, facilities and equipment to become the leader in dermal toxicology,” commented Ian Lennox, CEO of Ricerca. “We are proud to present this webinar and share our expertise with the industry.”
Ricerca Biosciences provides a full range of preclinical services from early discovery medicinal chemistry, compound screening, profiling and lead optimization through full drug safety, metabolism and efficacy development support, as well as clinical supply and commercial API production capability.
About Ricerca Biosciences
Ricerca Biosciences, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S.-based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon facility also holds AAALAC certification.
Kelly Sladek, 308-237-5567
KEYWORDS: United States North America Ohio
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Research Science